| abstract |
Use of an aromatase inhibitor for the preparation of a medicament to improve the implantation rate in an infectious patient who undergoes an in vitro fertilization (IVF), an intra-tubal transfer system of gametes (GIFT), an intra-tubal transfer procedure of zygotes (ZIFT), an intracytoplasmic sperm injection (ICSI) or a therapeutic donor insemination (TDI), in which the medication is for administration in the form of one or more daily doses of an aromatase inhibitor (AI) during a assisted reproduction cycle, and in which the doses of AI are selected from effective amounts to reduce serum estradiol levels. |